Using its regenerative medical product “CL 2020”, the trials are directed towards secondary prevention after treatment of acute myocardial infarction. The safety, tolerability and effectiveness at a single administration of CLIOs MUSE-cells (Multilineage-differentiating Stress Enduring cell) will be studied in 6 subject cases for one and a half year. After another trial, it is aimed to launch the product in FY 2021 utilizing the conditional deadline approval system of MHLW.

LSI Medience Corporation press release, January 15, 2018